• Ascendis Pharma (NasdaqGS:ASND) reported new 104 week data from its pivotal ApproaCH trial of once weekly TransCon CNP in children with achondroplasia.
• The long term results show sustained improvements in lower extremity alignment and growth outcomes, with continued safety and tolerability over two years of treatment.
• The company also highlighted that YUVIWEL, the commercial name for TransCon CNP, is approved in the US and remains under regulatory review at the EMA in Europe.

Ascendis Pharma focuses on endocrinology rare disease treatments, and TransCon CNP sits at the center of its achondroplasia franchise. With YUVIWEL already cleared in the US and under EMA review, the newly released two year data feed into an area of active interest for investors tracking rare disease therapies and long acting biologics. The results speak directly to long term treatment goals that matter to clinicians, patients, and payers in this niche.

For investors watching NasdaqGS:ASND, the combination of long horizon clinical data and parallel regulatory work in Europe may shape how the company allocates capital, partners, and communicates its growth strategy. The next phases of regulatory review, reimbursement discussions, and potential geographic expansion could influence how Ascendis Pharma prioritizes its broader pipeline and commercial footprint.

Stay updated on the most important news stories for Ascendis Pharma by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Ascendis Pharma.

Quick Assessment

• ⚖️ Price vs Analyst Target: Ascendis Pharma trades at US$270.45 versus a consensus target of about US$297.10, roughly 9% below that level.
• ✅ Simply Wall St Valuation: Shares are flagged as trading about 58.9% below an estimated fair value, which screens as undervalued.
• ✅ Recent Momentum: The stock is up 24.0% over the past 30 days, showing strong recent momentum.

There's only one way to know the right time to buy, sell or hold Ascendis Pharma. Head to Simply Wall St's company report for the latest analysis of Ascendis Pharma's Fair Value.

Key Considerations

• 📊 The 104 week TransCon CNP data strengthens the clinical story around YUVIWEL. The shares trade on a P/E of 29.7, compared with a Biotechs industry average of 17.4.
• 📊 Watch progress of the EMA review, uptake trends in the US launch, and how much YUVIWEL contributes to revenue and earnings over time.
• ⚠️ Recent significant insider selling and a high level of non cash earnings are key flags to keep in mind when assessing Ascendis Pharma.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Ascendis Pharma analysis. Alternatively, you can check out the community page for Ascendis Pharma to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.